Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Qinzhu Yang, Haofan Huang, Guizhi Zhang, Nuoqing Weng, Zhenkai Ou, Meili Sun, Huixing Luo, Xuhui Zhou, Yi Gao, Xiaobin Wu
BACKGROUND: In view of the fact that radiomics features have been reported as predictors of immunotherapy to various cancers, this study aimed to develop a prediction model to determine the response to anti-programmed death-1 (anti-PD-1) therapy in esophageal squamous cell carcinoma (ESCC) patients from contrast-enhanced CT (CECT) radiomics features. METHODS: Radiomic analysis of images was performed retrospectively for image samples before and after anti-PD-1 treatment, and efficacy analysis was performed for the results of two different time node evaluations...
September 24, 2023: Thoracic Cancer
#2
JOURNAL ARTICLE
Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Haiyan Xu, Yan Wang
BACKGROUND: Although some targeted therapies have been shown to be effective in treating HER2-altered non-small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study aimed to assess the effectiveness and safety of pyrotinib plus antiangiogenic agents, including apatinib, anlotinib, and bevacizumab, in previously treated patients with HER2-altered advanced NSCLC. METHODS: In this retrospective real-world study, patients with HER2-altered NSCLC who received pyrotinib plus antiangiogenic agents as a second- or later-line treatment between November 2015 and January 2022 were reviewed...
September 23, 2023: Thoracic Cancer
#3
REVIEW
Qing Zhao, Jing Wang, Yi-Li Fu, Bin Hu
Pulmonary carcinoma represents the second common cancer for human race while its mortality rate ranked the first all over the world. Surgery remains the primary option for early-stage non-small cell lung cancer (NSCLC) in some surgical traditions. Nevertheless, only less than half of patients are operable subjected to the limited lung function and multiple primary/metastatic lesions. Recent improvements in minimally invasive surgical techniques have made the procedure accessible to more patients, but this percentage still does not exceed half...
September 23, 2023: Thoracic Cancer
#4
JOURNAL ARTICLE
Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chuang
BACKGROUND: Despite the well-established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), there is limited real-world evidence comparing their effectiveness according to patients' clinical characteristics. This network meta-analysis (NMA) compared survival outcomes among first-line EGFR-TKIs in different subgroups of East Asian patients with advanced NSCLC. METHODS: This NMA included real-world observational studies reporting outcomes with TKIs in patients aged >65 years, with baseline brain metastasis, with different Eastern Cooperative Oncology Group (ECOG) statuses, or with different common EGFR mutation types...
September 22, 2023: Thoracic Cancer
#5
JOURNAL ARTICLE
Zhiguo Peng, Xinyue Dong, Miao He, Yajing Zhao, Yujia Liu, Mo Li, Guosheng Li, Xiuwen Wang, Li Li, Yu Hu
BACKGROUND: Th22 subset is a particular type of CD4+ T helper cells subset. Our study aimed to explore the expression level of circulating Th22, Th17, Th1, and Th2 cells and the possible mechanism of these cells in breast cancer (BC) with different pathological features. METHODS: Our study enrolled 43 newly diagnosed BC patients and 30 healthy controls. Frequencies of peripheral Th22, Th17, Th1, and Th2 cells were tested by flow cytometry. Concentrations of IL-22 cytokine in plasma were examined by enzyme-linked immunosorbent assay (ELISA)...
September 21, 2023: Thoracic Cancer
#6
JOURNAL ARTICLE
Tara L Peters, Nan Chen, Logan C Tyler, Anh T Le, Anastasios Dimou, Robert C Doebele
BACKGROUND: The vast majority of patients with ROS1 positive non-small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinical benefit and demonstrate rapid disease progression. The biological mechanisms underpinning intrinsic resistance remain poorly understood for oncogene-driven cancers. METHODS: We generated a patient-derived cell line, CUTO33, from a ROS1 therapy naive patient with CD74-ROS1+ NSCLC, who ultimately did not respond to a ROS1 inhibitor...
September 19, 2023: Thoracic Cancer
#7
JOURNAL ARTICLE
Shanbo Zheng, Juan Liao, Mingjun Sun, Ran Liu, Junjie Lv
BACKGROUND: Cell-cell communication by carcinoma-derived exosomes can influence the tumor microenvironment (TME) and regulate cancer progression. Based on the overexpression of microRNA-21-5p (miR-21) in plasma from patients diagnosed with esophageal squamous cell carcinoma (ESCC) and exosomes from ESCC cell lines identified earlier, this study aimed to explore the influence of exosomal miR-21 within the TME. METHOD: ScRNA-Seq and Bulk RNA-Seq were integrated to elucidate the communication between cancer and endothelial cells...
September 19, 2023: Thoracic Cancer
#8
JOURNAL ARTICLE
Fan Yang, Min Tang, Liang Cui, Jing Bai, Jiangyong Yu, Jiayi Gao, Xin Nie, Xu Li, Xuefeng Xia, Xin Yi, Ping Zhang, Lin Li
BACKGROUND: The biomarkers of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC) patients have limited predictive performance. In this study we aimed to investigate the feasibility of molecular tumor burden index (mTBI) in circulating tumor DNA (ctDNA) as a predictor for immunotherapy in patients with NSCLC. METHODS: From February 2017 to November 2020, pretreatment and on-treatment (3~6 weeks after first cycle of immunotherapy) dynamic plasma ctDNA samples from NSCLC patients receiving immune monotherapy or combination therapy were analyzed by targeted capture sequencing of 1021 genes...
September 19, 2023: Thoracic Cancer
#9
JOURNAL ARTICLE
Xingxiang Pu, Chunwei Xu, Qian Wang, Wenxian Wang, Fang Wu, Xiuyu Cai, Zhengbo Song, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Jingping Yuan, Zhansheng Jiang, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Weiwei Pan, Fei Pang, Jintao Huang, Kai Wang, Fan Wu, Tingting Shen, Shirui Zou, Bingwei Xu, Liping Wang, Youcai Zhu, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jing Kang, Jiatao Zhang, Chao Zhang, Jianfei Fu, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Yue Hao, Zhen Wang, Bing Wan, Donglai Lv, Gang Lan, Shengjie Yang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Yuan Li, Zhefeng Liu, Nong Yang, Huijuan Wang, Wenbin Huang, Zhuan Hong, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Xixu Zhu, Yi Shen, Yiping Zhang, Shenglin Ma, Yong Song, Yuanzhi Lu, Wenfeng Fang, Ziming Li, Lin Wu
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth and differentiation. In non-small cell lung cancer (NSCLC), RET fusion is a rare driver gene alteration associated with a poor prognosis. Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles. These inhibitors have shown the ability to overcome resistance to multikinase inhibitors (MKIs)...
September 18, 2023: Thoracic Cancer
#10
JOURNAL ARTICLE
Ming-Sheng Wu, Zheng-Wei Chen, Xiao Chen, Gao-Xiang Wang, Chun-Sheng Xu, Yong-Fu Zhu, Ming-Ran Xie
BACKGROUND: To explore the altered functional connectivity (FC) of the nucleus tractus solitarii (NTS) in patients with chronic cough after lung surgery using resting-state functional magnetic resonance imaging (rs-fMRI), and the association between abnormal FC and clinical scale scores. METHODS: A total of 22 patients with chronic cough after lung surgery and 22 healthy controls were included. Visual analog scale (VAS), Mandarin Chinese version of the Leicester Cough Questionnaire (LCQ-MC), and Hamilton anxiety rating scale (HAMA) scores were assessed, and rs-fMRI data were collected...
September 17, 2023: Thoracic Cancer
#11
REVIEW
Kewei Song, Chenhui Ma, Baohong Gu, Bofang Wang, Huanhuan Ma, Xiaobo Deng, Hao Chen
Esophageal cancer (EC) occupies the seventh spot of the most prevalent malignancy cancer ailments worldwide and the sixth leading cause of cancer-related death. Esophageal squamous cell carcinoma (ESCC) is also the most predominant histological subtype of EC, and cisplatin (DDP) is commonly used as a first-line chemotherapeutic drug for the late advanced stages of the disease. However, the emergence of drug resistance during clinical treatment possesses a significant challenge to the therapeutic success and patient outcomes...
September 17, 2023: Thoracic Cancer
#12
JOURNAL ARTICLE
Yi-Chun Hua, De-Zhi Gao, Kuan-Yu Wang, Xiao-Sheng Ding, Wei-Ran Xu, Yu-Bin Li, Wei-Wei Shi, Shi-Bin Sun, Xiao-Yan Li
BACKGROUND: The aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases. METHODS: A retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 lesions) who were admitted to our oncology and Gamma Knife center from January 2020 to May 2022. All patients received intracranial SRT and had PTBE. Based on treatment with Bev, patients were categorized as SRT + Bev and SRT groups...
September 17, 2023: Thoracic Cancer
#13
JOURNAL ARTICLE
Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Sato, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Shinohara Tsutomu, Yasuhiko Nishioka
BACKGROUND: Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non-small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we conducted a phase II study to elucidate the efficacy of pemetrexed (PEM) plus bevacizumab (Bev) combination chemotherapy in elderly patients with nonsquamous NSCLC. METHODS: A total of 29 elderly patients (≥75 years old) with nonsquamous NSCLC were enrolled in this multicenter, open-label, phase II study, and 27 patients were finally analyzed...
September 17, 2023: Thoracic Cancer
#14
JOURNAL ARTICLE
Lev Freidkin, Moshe Heching, Dror Rosengarten, Barak Pertzov, Evgeni Gershman, Shimon Izhakian, Shai M Amor, Mordechai Reuven Kramer
BACKGROUND: Right middle lobe (RML) syndrome is a recurrent or chronic obstruction of the RML causing atelectasis of the right middle lobe due to mechanical and nonmechanical etiologies. The consequences of untreated RML syndrome range from chronic cough to post-obstructive pneumonia and bronchiectasis. We report here our bronchoscopy experience in patients with RML syndrome. METHODS: We conducted a retrospective study of adult patients who underwent bronchoscopy for RML syndrome at Rabin Medical Center from 2008 through 2022...
September 13, 2023: Thoracic Cancer
#15
JOURNAL ARTICLE
Yangchun Gu, Jinyu Yu, Haifeng Hu, Hua Zhang, Baoshan Cao, Li Liang
BACKGROUND: Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non-small cell lung cancer (NSCLC) remains unclear. METHODS: We analyzed EGFR ex19del subtypes in NSCLC patients receiving first-line tyrosine kinase inhibitor (TKI) therapy at our center (January 2018-June 2022) and correlated them with median progression-free survival (mPFS) and median overall survival (mOS). RESULTS: We identified 17 different EGFR ex19del variants in 101 patients...
September 13, 2023: Thoracic Cancer
#16
JOURNAL ARTICLE
Haoran Zhang, Dongming Zhang, Jia Liu, Yuequan Shi, Xiaoyan Liu, Minjiang Chen, Wei Zhong, Jing Zhao, Yan Xu, Mengzhao Wang
BACKGROUND: DNA damage response (DDR) pathways are essential to sustain genomic stability and play a critical role in cancer development and progression. Here, we investigated the profile of DDR gene mutations in early-stage non-small cell lung cancer (NSCLC) and their prognostic values. METHODS: We first examined 74 DDR genes involved in seven DDR pathways and then focused on six specific genes: ATM, BRCA1, BRCA2, CHEK1, BARD1, and BRIP1. A total of 179 stage I and IIIa NSCLC patients who received curative resection in Peking Union Medical College Hospital and their corresponding samples were collected for DNA sequencing, immunohistochemistry and survival analysis...
September 13, 2023: Thoracic Cancer
#17
JOURNAL ARTICLE
Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wang
BACKGROUND: The comparative efficacies of different generation tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) remain largely unknown. Moreover, whether one EGFR-TKI confers superior survival remains unclear, especially in East Asians. We conducted a network meta-analysis (NMA) comparing the survival outcomes of East Asian patients with advanced NSCLC treated with first-line EGFR-TKIs. METHODS: The NMA included observational real-world evidence studies on adult patients with EGFR-mutated advanced NSCLC who received first (gefitinib and erlotinib), second (afatinib), or third (osimertinib) generation EGFR-TKIs as frontline therapy...
September 13, 2023: Thoracic Cancer
#18
Kosuke Masuda, Yoshiaki Nagai, Hikari Amari, Hiroki Tahara, Yuki Maeda, Jun Shiihara, Hiromitsu Ohta, Masahiro Hiruta, Yasuhiro Yamaguchi
Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74-year-old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durvalumab for metastatic recurrence confined to the mediastinal lymph nodes. Three weeks later, multiple randomly distributed nodular shadows appeared on chest CT, and thoracoscopic lung biopsy led to the diagnosis of multiple pulmonary metastases...
September 12, 2023: Thoracic Cancer
#19
JOURNAL ARTICLE
Jun Sugisaka, Yukihiro Toi, Yosuke Kawashima, Yutaka Domeki, Tomoiki Aiba, Sachiko Kawana, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
BACKGROUND: There is no well-established late-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Therefore, we retrospectively determined the efficacy and safety of platinum rechallenge with paclitaxel-carboplatin and bevacizumab in patients with nonsquamous NSCLC as a late-line therapy in a clinical setting. METHODS: Thirty patients with nonsquamous NSCLC who received paclitaxel-carboplatin with bevacizumab therapy as a late-line treatment at Sendai Kousei Hospital (Miyagi, Japan) between December 2011 and December 2021 were enrolled into the study...
September 12, 2023: Thoracic Cancer
#20
JOURNAL ARTICLE
Jiwon Kim, Chang-Min Choi, Wonjun Ji, Jae Cheol Lee
BACKGROUND: As the outcome of immunotherapy can be improved when concurrently or sequentially combined with cytotoxic chemotherapy or radiotherapy, we investigated the efficacy of immunotherapy maintenance following platinum-based chemotherapy in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (EGFR-TKI) failure. METHODS: In this prospective, open-label, single arm phase 2 trial, we enrolled patients aged 18 years or older with EGFR-mutant NSCLC, which progressed after first- or second-line EGFR-TKI...
September 12, 2023: Thoracic Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
